BLOG
What is the Big Deal about Quantitative Thresholds?
What is the Big Deal about Quantitative Thresholds? | by: Deneen Fumich, RPh | Article Posted: January 30, 2023 | Since July 21, 2021, industry has been hearing, reading and discussing the 10-year court ordered agreement better known as the “Injunctive Relief” which 3...
Recent Articles
COVID-19 Special Edition Part II: India and US React
This week, we provide more information on the short-term and long-term solutions that India and the United States have taken to protect their drug supply chain.
2020 Update: Continuing Pressure on Drug Manufacturers
With the developments around COVID-19, the drug manufacturers that working on a cure for the virus have been praised as (potential) saviors across the globe. This is a stark change to how they have regarded over the last few years – drug manufacturers have faced significant scrutiny due to a variety of issues including the opioid epidemic, generic price-fixing and price increases.
The Coronavirus and the Pharmaceutical Supply Chain
The Coronavirus and the Pharmaceutical Supply Chain As the coronavirus wreaks havoc around the globe, the pharmaceutical supply chain needs to...
AmerisourceBergen Reprimanded for Ineffective Suspicious Order Monitoring
AmerisourceBergen Reprimanded for Ineffective Suspicious Order Monitoring The settlement between the California Board of Pharmacy and...
How Telemedicine Has Made Generic Drugs Sexy
How Telemedicine Has Made Generic Drugs Sexy Since 2017, Direct-to-Consumer (DTC) startups (some engaged by Pharma Solutions!) have cropped up to...
DEA SOM 2020 Updates
Over two years in the making, the light at the end of the tunnel is finally in sight – the Drug Enforcement Administration’s (DEA) update to the infamous definition of a “suspicious order” may only be a few months away. In Fall 2017, the DEA drafted proposed an update to “to revise its regulations relating to suspicious orders of controlled substances,” per RIN 1117-AB47. The new rule will also further specify “the procedures a registrant must follow upon receiving such orders.”
